Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Otenaproxesul

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
    Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

    02 Apr 2024

    // FINANCIAL TIMES

    https://markets.ft.com/data/announce/full?dockey=600-202404010700BIZWIRE_USPRX____20240401_BW046957-1

    FINANCIAL TIMES
    02 Apr 2024
    Share Share
    Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
    Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting

    20 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240320913781/en

    BUSINESSWIRE
    20 Mar 2024
    Share Share
    Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
    Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul

    28 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230928171285/en

    BUSINESSWIRE
    28 Sep 2023
    Share Share
    Antibe Provides Development Update for Otenaproxesul
    Antibe Provides Development Update for Otenaproxesul

    12 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221012005448/en

    BUSINESSWIRE
    12 Oct 2022
    Share Share
    Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
    Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022

    06 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220906005405/en

    BUSINESSWIRE
    06 Sep 2022
    Share Share
    Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results
    Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results

    15 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220815005193/en

    BUSINESSWIRE
    15 Aug 2022
    Share Share